Drugs / Engineered immune effector cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03614650 | Jul 2025 → Jun 2028 expected | cancer | Shenzhen Geno-Immune Medical Institute | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Engineered immune effector cells | “Engineered immune effector cells (EIE)” NCT03614650 ↗ |
| Known as | EIE | “Engineered immune effector cells (EIE)” NCT03614650 ↗ |
| Modality | Cell therapy | “infusion of autologous gastro-intestinal (GI) cancer antigen-specific engineered immune effector cells (EIE)” NCT03614650 ↗ |
| Route | Intravenous | “by intravenous and intratumoral injections” NCT03614650 ↗ |